Related by context. All words. (Click for frequent words.) 84 Orphan Drug designation 80 orphan designation 79 orphan drug 76 Orphan Drug status 74 orphan medicinal product 74 Fast Track Status 73 Orphan Designation 73 Orphan Drug Status 73 Orphan Medicinal Product 73 Orphan Status 73 Orphan designation 72 Fast Track Designation 72 Fast Track designation 71 FDA Orphan Drug 71 Orphan Drug 70 Orphan Drug designations 68 granted orphan 67 Marketing Authorization 67 Granted Orphan Drug 67 Priority Review 66 OMP designation 66 Positive Opinion 66 Receives Orphan Drug Designation 65 Marketing Authorisation 65 Application MAA 64 Cellegesic 64 Marketing Authorisation Application 64 Fast Track designations 64 Icatibant 64 Civacir 64 TEMODAL 63 Accelerated Approval 63 Receives Orphan Drug 63 Vandetanib 63 Product Designation 63 Marketing Authorization Application 63 Receives Fast Track 63 Firazyr 63 Tostrex 63 ATryn R 63 Pivotal Phase III 63 SYCREST 63 GTC recombinant human 62 FDA Accepts 62 Preotact 62 Evoltra TM 62 Meets Primary Endpoint 62 Kepivance 62 Friedreich Ataxia FRDA 62 rilonacept 62 granted Orphan Drug 62 Expanded Indication 62 Loramyc R 62 Receives Positive Opinion 62 Noxafil 62 GTC recombinant form 62 Receives Marketing Authorization 61 XIAPEX ® 61 Evoltra ® 61 FOLOTYN ® 61 Archexin 61 NDA Submission 61 Orphan Drugs 61 Pirfenidone 61 Biologics License Application 61 Trobalt 61 Preotact R 61 Kuvan R 61 granted orphan medicinal 61 Soliris TM eculizumab 61 Patent Covering 61 Files IND 61 Amrubicin 61 Etanercept 61 Satraplatin 60 CryoSeal FS System 60 NEBIDO R 60 SEBIVO 60 Loramyc ® 60 Psoriasis Drug 60 ADVEXIN p# therapy 60 ATryn ® 60 Adenuric R 60 Glybera R 60 Medicinal Products EMEA 60 Sanvar R 60 Evoltra R 60 ELIQUIS 60 FDA Approvable Letter 60 SNT MC# 60 Personalized Immunotherapy 60 Aviptadil 60 Raptiva R 60 clofarabine 60 Marketing Authorization Application MAA 60 Pixantrone 60 Evoltra 60 Rhucin ® 60 FDA Clearance 60 Mepact 60 Phase III Clinical Trial 60 Somatuline Depot 60 Lambert Eaton Myasthenic 60 Abstral 60 Phase IIb Trial 60 Nimotuzumab 60 Aloxi R 60 Nexavar ® 60 Application BLA 60 FIRAZYR 60 Qualified Therapeutic Discovery 60 acyclovir Lauriad R 60 Advexin 60 CHMP recommendation 60 Torisel 60 Mimpara 60 Aryplase 60 Santhera 60 Romiplostim 59 Development OOPD 59 NOXAFIL 59 BENLYSTA ® 59 Alvesco R 59 ADVEXIN 59 Phase 2b Clinical Trial 59 Ustekinumab 59 Peginterferon alfa 2b 59 Dupuytren Contracture 59 BYETTA ® 59 Iluvien ® 59 BioWa 59 Jevtana 59 Epratuzumab 59 ZEFTERA TM Zevtera TM 59 Zelrix 59 Actemra tocilizumab 59 Completes Patient Enrollment 59 Yondelis ® 59 Cethrin 59 Thrombin topical Recombinant 59 BENLYSTA 59 Milestone Payments 59 Mutual Recognition Procedure 59 Onconase 59 PNP inhibitor 59 Orapred ODT 59 eltrombopag 59 Allovectin 7 59 Romidepsin 59 Febuxostat 59 Zingo TM 59 RAPAFLO 59 drug ISA# 59 Grants Orphan Drug 59 Junovan 59 Submits NDA 59 PGL# 59 Panzem R 59 ELAPRASE 59 Zenpep 59 Intravenous CP 59 Orphan Drug Act 59 Esbriet pirfenidone 59 Initiates Phase II 59 Pazopanib 59 Files Investigational 59 Zebinix R 59 Cimzia certolizumab pegol 59 investigational humanized monoclonal antibody 59 MEPACT 59 cinacalcet HCl 59 Syndrome LEMS 59 Drug Candidate 59 rasagiline tablets 58 Rituxan rituximab 58 FACTIVE R gemifloxacin 58 Initiate Clinical Trial 58 Cutaneous T 58 Bendamustine 58 TheraCIM 58 Ciclesonide 58 Ceplene 58 Therapeutic Discovery Project 58 Government Qualifying Therapeutic 58 LUCASSIN 58 Zorbtive TM 58 MyVax R 58 MAA submission 58 liver resection surgeries 58 SEASONALE R 58 sorafenib tablets 58 Pivotal Trial 58 PREOS R 58 RELISTOR ® 58 Fibrillex TM 58 Apricus Bio 58 PDUFA Date 58 dextromethorphan quinidine 58 Bronchitol 58 Increlex R 58 Pralatrexate 58 Ceflatonin 58 TYZEKA 58 Soliris eculizumab 58 Maribavir 58 SUMAVEL DosePro 58 Orphan medicinal 58 Intravenous Human 58 FRDA 58 targeted radiotherapeutic 58 IL# PE#QQR 58 Liprotamase 58 Milestone Payment 58 taliglucerase alfa 58 Tezampanel 58 ISTODAX ® 58 Thelin TM 58 Esbriet ® 58 Teflaro 58 Phenoptin 58 DAVANAT ® 58 Virulizin R 58 ACOMPLIA R 58 ThermoDox R 58 Gendux 58 Luveniq 58 OMAPRO ™ 58 Expedited Review 58 Acute Attacks 58 AA amyloidosis 58 Oracea ® 58 VPRIV 58 Synerx Pharma 58 Pivotal Phase 58 Supplemental Biologics License Application 58 Ceflatonin R 58 Removab 58 Aloxi ® 58 Zenvia ™ 58 methylnaltrexone 58 ankylosing spondylitis psoriatic arthritis 58 Wyeth Torisel 58 Vasovist 58 Modrenal R 58 tamibarotene 58 oncology indications 58 Prestara 58 Argatroban 58 Fortical R 58 GRAS Status 58 XIAFLEX ™ 58 XGEVA 58 StaphVAX R 58 ZALBIN 58 Factor VIIa 58 Rifaximin 58 BLA submission 58 Granulocyte Colony Stimulating Factor 58 Plenaxis R 58 Raptiva ® 58 Clavis Pharma 58 Neulasta R 58 Fodosine 58 nasal calcitonin product 58 Mylan Receives Approval 58 TNF Tumor Necrosis Factor 58 Keppra ® levetiracetam 58 Ceplene R 57 #D#C# 57 Aztreonam Lysine 57 successfully commercialize Iluvien 57 Li Fraumeni Syndrome 57 LHRH antagonist 57 post menopausal osteoporosis 57 submitted Biologics License 57 PDE4 inhibitor 57 prGCD 57 proprietary transdermal patch 57 Arzerra ofatumumab 57 VIDAZA 57 Tarceva TM 57 Investigational Device Exemption 57 Hycamtin 57 Marqibo 57 satraplatin 57 Patent Broadly Covering 57 Initiates Enrollment 57 Pfizer Sutent 57 Perifosine 57 Dyloject TM 57 Marketing Authorization Applications 57 Investigational Treatment 57 Clofarabine 57 Rhucin ® recombinant 57 TORISEL TM 57 Advanced Melanoma 57 formerly LymphoStat B 57 PROMACTA 57 Receives Milestone Payment 57 Initiates Phase III 57 Enzyme Replacement Therapy 57 CIMZIA r 57 Gamunex C 57 Patient Enrollment 57 Phase III Trial 57 ONCASPAR 57 SUMAVEL 57 Ridaforolimus 57 RAPTIVA 57 vemurafenib 57 BiovaxID TM 57 OHR/AVR# 57 Approvable Letter 57 Allovectin 7 R 57 Traficet EN 57 Recombinant Human 57 histone deacetylase HDAC inhibitor 57 YONDELIS 57 Receives Approvable Letter 57 Nabi HB R 57 SURFAXIN 57 Xyrem ® 57 ATryn ® GTC recombinant 57 methylnaltrexone bromide 57 Fresenius Biotech 57 Oral BDP 57 Investigational Compound 57 Loramyc 57 Alseres 57 Campath alemtuzumab 57 ATG Fresenius S 57 Golimumab 57 commercialize oritavancin 57 ZEVALIN ® 57 Sensipar R 57 GATTEX TM 57 OMNARIS HFA 57 AnGes 57 Zalbin 57 velaglucerase alfa 57 SUTENT ® 57 TREANDA 57 submitted Marketing Authorization 57 topical NSAID 57 SUPPRELIN R LA 57 PEGylated Fab fragment 57 Orathecin 57 cutaneous T 57 silodosin 57 Onco TCS 57 Complete Response 57 Bezielle 57 Biologic License Application 57 Expression Genetics 57 Xanafide 57 MAGE A3 ASCI 57 Loramyc ™ 57 Biological License Application 57 MPS VI 57 Prolongs Survival 57 Somatuline R Autogel R 57 Crofelemer budesonide foam 57 CINTREDEKIN BESUDOTOX 57 MabCampath 57 Filgrastim 57 REMICADE infliximab 57 HDAC Inhibitor 57 Generic Version 57 maribavir 57 USFDA approval 57 Ophthotech 57 Ambrisentan 57 Cladribine Tablets 57 ocular formulation 57 InNexus Biotechnology 57 Cetrorelix 57 JAK inhibitor 57 Centralized Procedure 57 VISICOL R 57 Junovan TM 57 miconazole Lauriad R 56 investigational compound 56 Fabry Disease 56 RANK Ligand inhibitor 56 ONCONASE 56 P#X# antagonist 56 LUVENIQ 56 Vion Pharmaceuticals 56 pseudobulbar affect PBA 56 systemic immunosuppressive drugs 56 Vidaza R 56 Carfilzomib 56 Prodarsan R 56 Biologics License Application BLA 56 CONBRIZA 56 eprodisate KIACTA TM 56 tiapamil 56 novel synthetic PEGylated 56 Cloretazine ® 56 Advagraf 56 Ranolazine 56 Pafuramidine 56 Exelixis XL# 56 talactoferrin 56 Rhucin R 56 Unit Dose Budesonide 56 briakinumab 56 Cinacalcet HCl 56 acetonide FA 56 Bafetinib 56 UPLYSO 56 XIAPEX 56 fipamezole 56 Belimumab 56 JAK Inhibitor 56 Bayer Onyx 56 mertansine 56 vinorelbine emulsion 56 Phase III Trials 56 Inhalation Aerosol 56 neovascular age 56 Monoclonal Antibody 56 OLEPTRO 56 Oracea TM 56 JOULFERON 56 Irinotecan 56 Ruconest 56 Juvantia 56 TORISEL 56 Alitretinoin 56 Rhucin 56 ATPace TM 56 Proxinium TM 56 Gencaro 56 Cimzia ® certolizumab pegol 56 Patient Enrolment 56 R bendamustine hydrochloride 56 RECOTHROM R 56 Sylvie Gregoire President 56 histamine dihydrochloride 56 BioDelivery Sciences 56 Esbriet 56 FIRMAGON R 56 oral prodrug 56 subcutaneous formulation 56 Gaucher Disease 56 Restanza 56 Vicinium TM 56 Emezine 56 Investigational 56 RECOTHROM ® 56 ThermoDox ® 56 IMA# 56 Orphan Products 56 relapsing multiple sclerosis 56 Microplasmin 56 RoACTEMRA 56 Certican 56 PREOS 56 Tetrabenazine 56 LibiGel ® 56 Ixempra 56 severe gastroparesis 56 Therapy Evaluation 56 DPP4 inhibitor 56 Qualifying Therapeutic Discovery 56 EnzymeRx 56 Bayer Nexavar 56 Mozobil 56 COLAZAL R 56 ZARS Pharma 56 Complicated Skin 56 AMITIZA R 56 atacicept 56 relapsing forms 56 Doripenem 56 REBETOL combination therapy 56 Indaflex TM 56 GVAX cancer 56 equine osteoarthritis 56 Naglazyme 56 Increlex TM 56 Anthim 56 Therapeutic Discovery 56 vapreotide acetate 56 mifamurtide 56 Initiate Phase II 56 Sycrest 56 orally administered inhibitor 56 Kuvan 56 Simulect 56 Voraxaze 56 Pradefovir 56 sBLA 56 Captisol enabled 56 Dapagliflozin 56 orBec 56 solifenacin succinate 56 IRESSA 56 Glufosfamide 56 Teva Provides Update 56 registrational 56 Brilique 56 markets Gelclair R 56 Initiate Phase III 56 Initiates Phase 56 Vitrasert R 56 LymphoStat B belimumab 56 Combination REOLYSIN R 56 European Medicines Evaluation 56 Arcalyst 56 Keppra ® XR 56 Testosterone Gel 56 gastrointestinal disorders characterized 56 Gleevec imatinib mesylate 56 filgrastim 56 herpetic keratitis 56 Phase IIb Clinical Trial 56 markets HP Acthar 56 Zirgan 56 SinuNase TM 56 Cimzia ® 56 Alemtuzumab 56 Dalbavancin 56 octreotide implant 56 IPLEX 56 Tibotec Therapeutics division 56 ONSOLIS 56 Drug Application 56 ARIXTRA R 56 Release Capsules 56 Aphthasol R 56 Successfully Completes Phase 56 oral ridaforolimus 56 metastatic hormone refractory 56 Urocidin 56 chronic idiopathic thrombocytopenic purpura 56 Gleevec Glivec 56 Combidex 56 Million Milestone Payment 56 sapropterin dihydrochloride 56 Pennsaid R 56 Vascugel 56 sunitinib malate 56 Milestone Payment From 56 rFVIIIFc 56 Valortim TM 56 etanercept Enbrel 56 DC Bead 56 Manja Bouman CEO 56 Metastatic Colorectal Cancer 56 Octreolin 56 DAVANAT R 56 StaphVAX 56 anticancer compound 56 Eprodisate KIACTA TM 56 BioAlliance 56 IMiDs ® compound 56 Completes Patient Enrolment 56 EVIZON TM 56 orBec R 56 Cinryze TM 56 Marketing Authorisation Application MAA 56 Gemzar ® 55 ® decitabine 55 THELIN 55 Rectogesic 55 Azedra 55 ONGLYZA ™ 55 DR Cysteamine 55 HepaGam B 55 Opterone R 55 MORAb 55 Aflibercept 55 Cimzia TM 55 Abstral ® 55 NPC 1C 55 receptor tyrosine kinase inhibitor 55 mesylate tablets 55 Initiates Clinical 55 Eraxis 55 Efficacy Results 55 IND Filing 55 Demonstrates Significant 55 Degarelix 55 Glatiramer Acetate 55 tafamidis 55 humanized monoclonal antibody 55 Nasdaq VNDA 55 Pivotal Study 55 erlotinib Tarceva R 55 Velaglucerase Alfa 55 Roche PEGASYS R 55 Biologic License Application BLA 55 POSIDUR TM ELADUR TM 55 IMiDs ® 55 ADP receptor antagonist 55 EPCT 55 Nabi HB Intravenous 55 TYKERB 55 TELINTRA 55 Octreotide 55 R adalimumab 55 Uplyso 55 XIAFLEX TM 55 YONDELIS R 55 Nexavar sorafenib 55 TolerRx 55 Nivestim 55 Drug Eluting Stent System 55 ProLindac TM 55 Eligard R 55 Isavuconazole 55 Hsp# Inhibitor 55 rhC1INH 55 autoimmune indications 55 Increlex ® 55 CIP TRAMADOL ER 55 PHX# 55 oral fludarabine 55 Completes Enrollment 55 Insegia 55 Vitaros 55 Lucanix R 55 injectable formulation 55 supplemental Biologics License Application 55 Herceptin trastuzumab 55 davunetide 55 CCR9 antagonist 55 Taro Receives 55 II Clinical Trial 55 Combination Therapy 55 submitted supplemental Biologics 55 vitreoretinal disorders 55 Promacta 55 Angiox 55 Sutent sunitinib 55 Etravirine 55 Clevudine 55 HuMax CD4 55 Ceftobiprole 55 Retacrit 55 Receives Complete Response 55 cell lymphoma CTCL 55 Phase 2a Clinical Trial 55 New Drug Application 55 Tygacil 55 palifermin 55 Keppra ® 55 targeting CD# 55 Syntonix 55 Initiates Clinical Trial 55 SCHWARZ PHARMA 55 Janssen Pharmaceutica NV 55 refractory chronic lymphocytic 55 PLK1 SNALP 55 Presents Preclinical Data 55 Advanced Renal Cell 55 novel histone deacetylase 55 Single Dose 55 Fludara ® 55 Orexo 55 Kiadis Pharma 55 ALN PCS 55 Alvesco ® 55 rheumatoid arthritis psoriatic arthritis 55 TRANSDUR ™ 55 Tesamorelin 55 Bioral 55 HuMax TAC 55 ALN TTR 55 Lenocta 55 Bazedoxifene 55 VitiGam TM 55 LEVADEX TM 55 ONGLYZA TM 55 Firdapse ™ amifampridine phosphate 55 Initiate Phase 55 Teysuno 55 levocetirizine 55 First Patient Dosed 55 Oral Spray 55 Bioral ® 55 Bioral R 55 Azacitidine 55 Diabetic Macular Edema 55 Genasense R 55 SomatoKine 55 oropharyngeal candidiasis 55 PreHistin TM 55 ALVESCO R 55 prostone 55 huC# DM4 55 Rescula 55 Keryx Biopharma 55 Sumatriptan Succinate 55 forodesine 55 regadenoson 55 humanized anti 55 AMITIZA lubiprostone 55 Inhalation Solution 55 k Clearance 55 Velac 55 Calcium Acetate 55 Cladribine 55 IAP inhibitors 55 Metastatic Melanoma 55 Elesclomol 55 targeted antifolate 55 REPLAGAL 55 Behcet uveitis 55 Xolegel 55 BioDelivery Sciences Announces 55 Present Preclinical Data 55 Metformin HCl 55 Japanese Encephalitis Vaccine 55 Submits Biologics License Application 55 Patients Treated With 55 KIACTA ™ 55 Sigma Tau Pharmaceuticals 55 MOZOBIL 55 STELARA TM 55 highly purified pasteurized 55 Avastin bevacizumab 55 Onalta ™ 55 Panzem 55 liposomal formulation 55 Submits Supplemental 55 Telatinib 55 Circ Pharma 55 reslizumab 55 Uvidem 55 lucinactant 55 MOVIPREP R 55 alvimopan 55 Submits Investigational 55 hoFH 55 SUPPRELIN LA 55 AzaSite Xtra 55 Onalta 55 R sorafenib tablets 55 FDA Approval 55 Severe Sepsis 55 Lenalidomide 55 Everolimus 55 eprodisate Fibrillex TM 55 SUTENT 55 SJIA 55 Phase III Clinical Trials 55 Bevacizumab 55 NerPharMa 55 Lubiprostone 55 IgG1 monoclonal antibody 55 Increlex 55 Ipilimumab 55 lexidronam injection 55 License Application sBLA 55 Eribulin 55 HuMax EGFr 55 TRISENOX R 55 anticancer agent 55 HepaSphere 55 generation purine nucleoside 55 Pemetrexed 55 human C1 inhibitor 55 Somatuline Autogel 55 experimental immunotherapeutics antivirals AmpligeGI mucosa resulting 55 Receives CE Marking 55 Humanitarian Device Exemption 55 investigational antiplatelet agent 55 Cethromycin 55 Elagolix 55 Veregen R 55 Zavesca r 55 Silodosin 55 AAG geldanamycin analog 55 CORT # 55 Loramyc TM 55 ZENPEP 55 INDs 55 BEXXAR 55 ARRY # 55 TRISENOX 55 Thalidomide Pharmion 55 CIP Fenofibrate 55 ANTEGREN 55 Announces Tentative Approval 55 Darunavir 55 5 lipoxygenase inhibitor 55 bazedoxifene 55 intravenous iclaprim 55 Onrigin 55 FDA Complete Response 55 Sevelamer 55 IND Investigational New 55 Aegera 55 PrevOnco ™ 55 KALBITOR ® 55 Act PDUFA date 55 OncoGel 55 Neuromodulation System 55 FDA APPROVES 55 Phase 2a Trial 55 Rapinyl 55 orphan medicinal 55 omacetaxine mepesuccinate 55 % uracil topical 55 nanofiltered plasma derived 55 dasatinib Sprycel ® 55 SFDA Approval 55 Rebif ® 55 CEQ# 55 hypereosinophilic syndrome 55 FUSILEV ® 55 ZACTIMA 55 Saforis 55 CINOD 55 Cx# [002] 55 FDA Modernization Act 55 lasofoxifene 55 application sNDA 55 Ilaris 55 candidate epratuzumab 55 Ofatumumab 55 Project QTDP program 55 Phase IIIb clinical 55 mitogen activated ERK kinase 55 Troxatyl 55 Ranexa R 55 NUEDEXTA ™ 54 L BLP# 54 Rilonacept 54 HCV Protease Inhibitor 54 Lung Cancer Drug 54 Novel Oral 54 Fentanyl TAIFUN R 54 alefacept 54 diarrhea predominant irritable 54 Firazyr ® 54 Dacogen injection 54 ZEGERID Chewable Tablets 54 VALSTAR 54 Oncoscience AG 54 Systemic Delivery 54 ixabepilone 54 DepoDur 54 REPEL CV 54 Leukine 54 IMiDs R 54 Aliskiren 54 sublingual tablets 54 FDA Approvals 54 induced macular edema 54 investigational pharmacologically unique 54 IV Busulfex 54 CIMZIA TM 54 Daclizumab 54 pitavastatin 54 Prostate Cancer Vaccine 54 panitumumab Vectibix 54 VIVITROL ® 54 proteasome inhibitor 54 recurrent refractory 54 Pulmonary Arterial Hypertension 54 Diamyd ® 54 amrubicin 54 dihydrochloride Tablets 54 Pluristem Therapeutics 54 GEM #S 54 oral iron chelator 54 Tasimelteon 54 Regulatory Approval 54 Levoleucovorin 54 Telavancin 54 terlipressin 54 Mipomersen 54 Humira adalimumab 54 GRAS notification 54 BENLYSTA TM 54 registrational studies 54 PrevOnco 54 TRANSDUR ® 54 Tesetaxel 54 PRTX 54 Albugon 54 IDM Pharma 54 polymerase inhibitor 54 M Enoxaparin 54 Adjuvant Treatment 54 Bosutinib 54 Commence Phase 54 NEBIDO 54 selective A2A adenosine receptor 54 GALNS 54 Angiox ® 54 Familial Adenomatous Polyposis FAP 54 SBIR Grant 54 recombinant biopharmaceutical 54 Regeneron Pharma 54 Fingolimod 54 PROVENGE ® 54 docetaxel Taxotere ® 54 sNDA 54 DORIBAX 54 amifampridine phosphate 54 motexafin gadolinium Injection 54 Nebido 54 human antithrombin 54 FOSRENOL 54 Torisel temsirolimus 54 Receive Milestone Payment 54 Study Evaluating 54 pralatrexate injection folate analogue 54 ABILIFY R 54 Clolar ® 54 BRILINTA 54 Talabostat 54 IMiD 54 PANVAC VF 54 registrational trial 54 HoFH 54 Oral Cladribine 54 EGRIFTA TM 54 Lodotra 54 Sumavel DosePro 54 oral taxane 54 pregabalin Lyrica 54 Taxotere ® 54 Long Term Efficacy 54 BAL# [002] 54 Afinitor ® 54 thymalfasin 54 delivers fluocinolone acetonide FA 54 cutaneous T cell 54 Pliaglis 54 samarium Sm 54 Kit CD# positive 54 PharmaMar 54 XIAFLEX ® 54 CNTO 54 ALN TTR# 54 Aegerion 54 Tasigna nilotinib 54 Immune Globulin Human 54 Subpart E 54 AVONEX ® 54 refractory Hodgkin lymphoma 54 CAMPATH R 54 Ceplene ® histamine dihydrochloride 54 Campath ® 54 Swedish Orphan Biovitrum 54 Submits Response 54 abiraterone acetate 54 therapeutic monoclonal antibodies 54 RhuDex ® 54 acyclovir Lauriad ® 54 Entocort 54 Inhaled Insulin 54 C1 Inhibitor 54 PEGylated anti 54 TheraQuest 54 Gout Drug 54 DOR BioPharma Announces 54 Nitec 54 Panzem R NCD 54 Erwinase 54 thalidomide Thalomid 54 ACZ# 54 HQK 54 Oracea 54 Neulasta ® 54 thetreatment 54 thrombolytic agent 54 molecular imaging radiopharmaceutical 54 Orazol 54 hyaluronidase enzyme 54 Besivance 54 Anticalin R 54 MuGard TM 54 Arimoclomol 54 Adjunctive Therapy 54 Xcytrin R 54 CLIA Waiver 54 Xyfid TM 54 exon skipping 54 Pivotal Phase II 54 Vidaza azacitidine 54 Blood Pressure Drug 54 pan HDAC inhibitor 54 Triapine 54 Treatment IND 54 Fortigel 54 post herpetic neuralgia PHN 54 Cancer Vaccine 54 Abiraterone acetate 54 Initiates Clinical Trials 54 Severe VOD 54 Virulizin 54 Drug Applications ANDAs